Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This clinical study is being conducted to identify the most effective drug concentration and
dose frequency of BOL-303242-X (Mapracorat) ophthalmic suspension, for the treatment of
inflammation following cataract surgery.